T1	intervention 92 117	HER2 peptide AE37 vaccine
T2	condition 155 165	recurrence
T3	eligibility 498 662	Clinically disease-free node-positive and high-risk node-negative breast cancer patients with tumors expressing any degree of HER2 [immunohistochemistry (IHC) 1-3+]
T4	control 727 739	GM-CSF alone
T5	outcome-Measure 765 785	Clinical recurrences
T6	outcome-Measure 806 833	disease-free survival (DFS)
T7	No-of-participants 863 866	298
T8	intervention-participants 877 880	153
T9	control-participants 908 911	145
T10	outcome 1074 1089	recurrence rate
T11	intervention-value 1118 1123	12.4%
T12	control-value 1131 1136	13.8%
T13	outcome 1278 1293	5-year DFS rate
T14	intervention-value 1298 1303	80.8%
T15	control-value 1325 1330	79.5%
T16	outcome 1382 1428	patients with IHC 1+/2+ HER2-expressing tumors
T17	outcome 1430 1440	5-year DFS
T18	intervention-value 1445 1450	77.2%
T19	intervention-value 1479 1481	76
T20	control-value 1490 1495	65.7%
T21	control-value 1521 1523	78
T22	outcome 1540 1583	patients with triple-negative breast cancer
T23	outcome 1631 1634	DFS
T24	intervention-value 1639 1644	77.7%
T25	intervention-value 1673 1675	25
T26	control-value 1684 1689	49.0%
T27	control-value 1715 1717	25
